ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Sterling to begin supplying hydroxychloroquine for UK market

by Rick Mullin
May 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

 

The British fine chemical maker Sterling Pharma Solutions will begin producing hydroxychloroquine, a malaria treatment under investigation for COVID-19, at its plant in Newcastle-upon-Tyne, England. Sterling will supply Accord Healthcare, which aims to make up to 50 million hydroxychloroquine tablets a month in Barnstaple, England. The partnership will establish UK supply of hydroxychloroquine, according to Sterling. Last month, Albany Molecular Research announced plans to increase hydroxychloroquine production in Rensselaer, New York.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment